Insulet shares rose 6.6% after the company reported third-quarter revenue growth of nearly 20% and narrowed its full-year 2026 revenue outlook to the top end of its prior range. The positive reaction comes alongside a note of caution: management expects to take a more conservative approach to its 2027 outlook as competition increases.
- Revenue was $842 million, up nearly 20% year over year: approximately 15% growth in the U.S. and 33% internationally.
- The global customer base grew more than 20%; new customer starts were up low single digits in Q3, though year-to-date starts grew low double digits.
- Type 2 patients accounted for over 40% of U.S. starts; more than 85% of Omnipod starts came from people switching from multiple daily injections.
- Management cited record gross margin and expanded operating margin, but gave no margin figures in the excerpt.
- The board approved an additional $1 billion in share repurchase authorization; Insulet expects to repurchase $400 million in Q4 using cash on hand.
Community Discussion